Major bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).
1 finding from 1 review
Myocardial infarction · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in myocardial infarction compared with warfarin; GRADE not reported.
1 finding from 1 review
Minor bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in minor bleeding compared with warfarin (low certainty).
1 finding from 1 review
Gastrointestinal bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in gastrointestinal bleeding compared with warfarin (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) probably leads to lower intracranial haemorrhage compared with warfarin (moderate certainty).
1 finding from 1 review
All‐cause mortality · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low